Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
02
2020
accepted:
21
05
2020
entrez:
15
9
2020
pubmed:
16
9
2020
medline:
7
5
2021
Statut:
ppublish
Résumé
The aim of the present study was to assess management strategies for immune thrombocytopenia (ITP) among Italian paediatric haematologists, and to compare these with those of recent international guidelines. Predictors of early remission or disease chronicity were also evaluated. During a period of 1 year, 205 children (age: 1 month-18 years) with newly diagnosed ITP were prospectively enrolled by 16 centres belonging to the Italian Association of Paediatric Haematology and Oncology (AIEOP). We collected the subjects demographic data, history, clinical symptoms, platelet count and treatment at presentation and at subsequent visits. Of the 205 patients, 47 (23%) were initially managed with a wait-and-see approach. Compared to these patients, children administered platelet-enhancing therapies were significantly younger (median age: 4.75 vs 7.96 years; p<0.001) and had lower platelet counts. At the 3-month follow-up, 92/202 patients (46%) had persistent ITP. Recovery within 3 months was predicted by younger median age (5.3 vs 7.8 years; p<0.001), and recent viral infection (p<0.001) . At 1 year, 56 patients had chronic ITP, which was associated with older median age (7.54 vs 5.35 years; p<0.001), and a family history of autoimmunity (p<0.05; relative risk: 1.81; 95% confidence interval: 1.09-2.98). In total, 357 pharmacological treatments were recorded (216 intravenous immunoglobulins, 80 steroids). Response to intravenous immunoglobulins did not have an effect on remission rate at 12 months. Pediatric hematologists in Italian Centre treat over three-quarters of patients with newly diagnosed ITP, despite recent international guidelines. Almost 80% of patients with mild clinical symptoms received pharmacological treatment at diagnosis, which was significantly associated with younger age. Chronicity at 12 months was not affected by different therapeutic approaches at diagnosis or response to therapy.
Sections du résumé
BACKGROUND
The aim of the present study was to assess management strategies for immune thrombocytopenia (ITP) among Italian paediatric haematologists, and to compare these with those of recent international guidelines. Predictors of early remission or disease chronicity were also evaluated.
MATERIALS AND METHODS
During a period of 1 year, 205 children (age: 1 month-18 years) with newly diagnosed ITP were prospectively enrolled by 16 centres belonging to the Italian Association of Paediatric Haematology and Oncology (AIEOP). We collected the subjects demographic data, history, clinical symptoms, platelet count and treatment at presentation and at subsequent visits.
RESULTS
Of the 205 patients, 47 (23%) were initially managed with a wait-and-see approach. Compared to these patients, children administered platelet-enhancing therapies were significantly younger (median age: 4.75 vs 7.96 years; p<0.001) and had lower platelet counts. At the 3-month follow-up, 92/202 patients (46%) had persistent ITP. Recovery within 3 months was predicted by younger median age (5.3 vs 7.8 years; p<0.001), and recent viral infection (p<0.001) . At 1 year, 56 patients had chronic ITP, which was associated with older median age (7.54 vs 5.35 years; p<0.001), and a family history of autoimmunity (p<0.05; relative risk: 1.81; 95% confidence interval: 1.09-2.98). In total, 357 pharmacological treatments were recorded (216 intravenous immunoglobulins, 80 steroids). Response to intravenous immunoglobulins did not have an effect on remission rate at 12 months.
DISCUSSION
Pediatric hematologists in Italian Centre treat over three-quarters of patients with newly diagnosed ITP, despite recent international guidelines. Almost 80% of patients with mild clinical symptoms received pharmacological treatment at diagnosis, which was significantly associated with younger age. Chronicity at 12 months was not affected by different therapeutic approaches at diagnosis or response to therapy.
Identifiants
pubmed: 32931416
pii: 2020.0041-20
doi: 10.2450/2020.0041-20
pmc: PMC7592159
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-405Références
Pediatr Hematol Oncol. 2014 Sep;31(6):534-47
pubmed: 24852656
Blood. 2018 Aug 30;132(9):883-891
pubmed: 29945954
Blood. 2009 Mar 12;113(11):2386-93
pubmed: 19005182
Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28111877
Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):650-2
pubmed: 16933271
Thromb Haemost. 2008 Jan;99(1):4-13
pubmed: 18217129
Br J Haematol. 2010 Jun;149(6):855-64
pubmed: 20377590
Haematologica. 2000 Apr;85(4):420-4
pubmed: 10756369
Lancet. 2001 Dec 22-29;358(9299):2122-5
pubmed: 11784627
J Pediatr. 2003 Sep;143(3):302-7
pubmed: 14517509
J Pediatr. 2019 Jan;204:320-323
pubmed: 30579471
J Pediatr. 2013 Nov;163(5):1335-9.e1-2
pubmed: 23891349
Blood Adv. 2019 Dec 10;3(23):3829-3866
pubmed: 31794604
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28792679
Patient Relat Outcome Meas. 2018 Nov 27;9:369-384
pubmed: 30568522
Acta Haematol. 2008;119(1):1-7
pubmed: 18176072
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
J Pediatr. 2017 Nov;190:265-267
pubmed: 28734656
Blood Transfus. 2014 Jul;12(3):340-5
pubmed: 24887226